Okogbenin Sylvanus Akhalufo, Erameh Cyril Oshomah, Egbuta Ola Chikerendu, Iraoyah Kelly Ohis, Onyebujoh Joy Thelma, Erohubie Christian Ehigbor, Jaggu Akolo Yohanna, Onovo Raymond, Avbuluimen Mercy, Odewale Modupeola Ajibike, Enigbe Elizabeth Ebosebhanlen, Ifada Ehinomen Cordilia, Okogbenin Esther Osemudiamen
Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, Edo State; ThisDay Dome Isolation and Treatment Centre for COVID-19, Abuja, Nigeria.
ThisDay Dome Isolation and Treatment Centre for COVID-19, Abuja; Department of Community Medicine; Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Niger Postgrad Med J. 2021 Apr-Jun;28(2):81-87. doi: 10.4103/npmj.npmj_532_21.
Coronavirus disease 2019 (COVID-19), a highly transmissible viral infection has spread worldwide causing exponential increase in morbidity and mortality. But so far, there is limited information available to describe the presenting characteristics, outcomes and treatment modalities of COVID-19 patients in Nigeria. This study aimed to describe the demographic and clinical characteristics, underlying comorbidities, treatment modalities and outcomes of patients isolated and treated in a repurposed COVID-19 isolation and treatment centre in Abuja, Nigeria.
A retrospective study which reviewed the medical records of 300 confirmed COVID-19 patients isolated and treated according to the World Health Organisation and Nigeria Centre for Disease Control guidelines between 22 July and 26 October, 2020 in ThisDay Dome Isolation and Treatment Centre. Data collected from the medical records include demographics, clinical features, treatment measures and outcomes.
Out of 300 patients studied, 61.0% were male. The mean age of the participants was 38.2 ± 14.7. Less than half of the patients (40.3%) had one or more underlying comorbidities with hypertension the most common co-morbidity. Majority (62%) of patients were mildly symptomatic, 33% were asymptomatic while only 2% were severely symptomatic. The most common presenting symptoms include cough 34.0%, fever 30.3%, anosmia 28.7% and dysgeusia 22.7%. Older age (P < 0.001), tertiary education and the presence of underlying comorbidity (P < 0.001) were significantly associated with symptomatic presentation of COVID-19. The median duration of time between positive laboratory testing and presentation for treatment was 5 days (0-29). All patients were treated with a combination of Ivermectin, Azithromycin, Zinc and Vitamin C with no recorded death. The median length of stay at facility was 9 days.
Close attention should be given to patients with co-morbidities as an inefficient management of such co-morbidities could lead to mortalities which may not be directly attributable to COVID-19.
2019年冠状病毒病（COVID-19）是一种高传染性病毒感染，已在全球范围内传播，导致发病率和死亡率呈指数级增长。但到目前为止，关于尼日利亚COVID-19患者的临床表现特征、治疗结果和治疗方式的可用信息有限。本研究旨在描述在尼日利亚阿布贾一个重新启用的COVID-19隔离和治疗中心隔离并接受治疗的患者的人口统计学和临床特征、潜在合并症、治疗方式及治疗结果。
一项回顾性研究，回顾了2020年7月22日至10月26日期间在《今日报》穹顶隔离和治疗中心按照世界卫生组织和尼日利亚疾病控制中心指南隔离并治疗的300例确诊COVID-19患者的病历。从病历中收集的数据包括人口统计学、临床特征、治疗措施和治疗结果。
在研究的300例患者中，61.0%为男性。参与者的平均年龄为38.2±14.7岁。不到一半的患者（40.3%）有一种或多种潜在合并症，其中高血压是最常见的合并症。大多数患者（62%）症状轻微，33%无症状，只有2%症状严重。最常见的临床表现包括咳嗽（34.0%）、发热（30.3%）、嗅觉丧失（28.7%）和味觉障碍（22.7%）。年龄较大（P<0.001）、受过高等教育以及存在潜在合并症（P<0.001）与COVID-19的症状表现显著相关。实验室检测呈阳性到接受治疗的中位时间为5天（0 - 29天）。所有患者均接受了伊维菌素、阿奇霉素、锌和维生素C的联合治疗，无死亡记录。在该机构的中位住院时间为9天。
应密切关注合并症患者，因为对这些合并症管理不善可能导致死亡，而这些死亡可能并非直接由COVID-19所致。
